TDP-43 Pathology in Motor Neuron Disease
In 2006, two groups independently discovered that a protein called TDP-43 forms the abnormal cytoplasmic inclusions found in the neurons of ALS patients. That single observation unified a field that had struggled to find the common thread connecting genetically distinct forms of the disease. Today, TDP-43 pathology is present in approximately 97% of all ALS cases — regardless of genetic cause — and in nearly half of frontotemporal dementia cases. It is the closest thing the ALS-FTD spectrum has to a universal pathological marker, and it is a primary target for therapeutic development. What it means for PLS is less clear, but evidence is accumulating.
What TDP-43 is and what it normally does
TDP-43 is an RNA- and DNA-binding protein encoded by the TARDBP gene on chromosome 1p36. Under normal conditions, TDP-43 resides primarily in the cell nucleus, where it participates in RNA metabolism — it helps regulate RNA splicing, transport, and stability, and it plays roles in the formation and dynamics of stress granules. Like many RNA-binding proteins, TDP-43 contains an intrinsically disordered low-complexity domain that enables it to undergo liquid-liquid phase separation: under the right conditions, it can condense into membraneless compartments that concentrate its activity.
The low-complexity domain that makes TDP-43 functionally flexible also makes it prone to aberrant aggregation. When the normal tight regulation of TDP-43 behavior breaks down — through genetic mutation, cellular stress, aging, or mechanisms not yet understood — TDP-43 misfolds, is phosphorylated and ubiquitinated, and accumulates in the cytoplasm as insoluble inclusions. This pathological TDP-43 is physically and biochemically distinct from the normal protein: the post-translational modifications (hyperphosphorylation, ubiquitination) serve as histological markers that allow neuropathologists to identify it in post-mortem brain and spinal cord tissue.
What the research has found
The core finding is that hyperphosphorylated, ubiquitinated TDP-43 cytoplasmic inclusions are present in the motor neurons and surrounding tissue of virtually all ALS patients at post-mortem examination. This is true for sporadic ALS, for ALS caused by C9orf72 expansion, for ALS caused by rare mutations in dozens of other genes — and for a minority of SOD1-ALS cases (though notably, classic SOD1-ALS with misfolded SOD1 accumulation often lacks TDP-43 pathology, suggesting SOD1-ALS may be a partial exception).
TDP-43 pathology correlates with neurodegeneration. Where TDP-43 inclusions are found, neurons are dying or have died. The inclusions are not passive bystanders — functional studies have established that cytoplasmic TDP-43 aggregation simultaneously depletes the nuclear pool of TDP-43 (causing loss-of-function effects on RNA metabolism) and generates toxic gain-of-function effects through the aggregated cytoplasmic species. Both mechanisms likely contribute to neuronal death.
A particularly important aspect of TDP-43 pathology is its apparent ability to propagate through neural tissue in a prion-like fashion. Abnormal TDP-43 can seed the misfolding of normal TDP-43 in adjacent cells, potentially explaining the regional spread of ALS — the observation that symptoms often begin in one region of the body and spread to contiguous motor regions over time. This prion-like propagation hypothesis is supported by cell culture and animal model data, though its role in human disease is still being characterized.
TARDBP mutations — missense changes in the gene encoding TDP-43 — cause a subset of familial ALS cases, estimated at 4–5% of familial ALS. These mutations cluster in the low-complexity domain and appear to enhance TDP-43's tendency to aggregate. But the much larger clinical significance of TDP-43 is as a convergent pathological endpoint: most ALS patients who develop TDP-43 pathology do not carry TARDBP mutations. Instead, TDP-43 mislocalization and aggregation is the final common pathway that many different upstream insults — genetic and non-genetic — funnel into.
TDP-43 inclusions have also been detected in cerebrospinal fluid and, with improving assays, in plasma. CSF and blood-based TDP-43 detection is an active area of biomarker development for ALS, with the potential to serve as both a diagnostic and a pharmacodynamic marker for therapies targeting TDP-43 pathology.
Why it matters for drug development
TDP-43 pathology is present in ~97% of ALS cases. If a therapy could prevent, reduce, or reverse TDP-43 cytoplasmic aggregation, it would theoretically have relevance across almost all ALS — regardless of the upstream genetic or environmental cause. This makes TDP-43 an extraordinarily attractive therapeutic target: it is not a rare subtype target like SOD1 (2% of cases) but a near-universal pathological feature.
Multiple approaches are in development. Vectorized antibody treatments delivered by gene therapy vectors are entering early clinical trials. Small molecules targeting the low-complexity domain aggregation process are in preclinical development. AP-2 (Molefy Pharma) targets restoration of normal TDP-43 balance as an investigational strategy. The challenge is that TDP-43's normal function — nuclear RNA processing — must be preserved even while its pathological cytoplasmic behavior is suppressed. Strategies that simply deplete TDP-43 risk causing the same nuclear loss-of-function that drives disease from the other direction.
What this means for PLS
The direct evidence for TDP-43 pathology in PLS is limited, primarily because PLS post-mortem studies are far fewer in number than ALS studies. Published case series suggest that TDP-43 inclusions are present in a subset of PLS patients at autopsy — consistent with PLS sharing some neuropathological features with ALS — but the data are not sufficient to say that TDP-43 pathology is as universal in PLS as it is in ALS.
The interpretation of this gap requires care. PLS patients live much longer than ALS patients, making post-mortem studies less common (patients survive to old age). The smaller number of published PLS autopsy studies means absence of evidence is not strong evidence of absence. There are credible reasons to think that at least some PLS cases involve TDP-43 pathology, particularly given the clinical and genetic overlap between PLS and ALS. But this remains an active area of uncertainty, not settled science.
For PLS patients, the practical implication is modest: TDP-43-targeting therapies developed for ALS would potentially be worth evaluating in PLS if TDP-43 pathology is confirmed as a common feature of the disease. This is one reason why the neuropathology of PLS — including systematic post-mortem studies with TDP-43 staining — is a research priority.
How this connects
TDP-43 pathology connects the C9orf72 and SOD1 stories — genetically distinct diseases that nevertheless converge on TDP-43 inclusions downstream. FUS, another RNA-binding protein in the same family as TDP-43, causes a smaller fraction of familial ALS through similar aggregation mechanisms. For TDP-43-targeting therapies now entering trials, see the Investigational Treatments page. For the overall biological relationship between ALS and PLS — including what the shared neuropathological features do and do not imply — see ALS Context. The Genetics Research hub explains where TDP-43 fits into the broader genetics landscape.
Citation
Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–133. doi:10.1126/science.1134108
Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochemical and Biophysical Research Communications. 2006;351(3):602–611.